Top Page
Enanta Pharmaceuticals
(NASDAQ:ENTA)
Enanta Pharmaceuticals (ENTA) vs. SPDR S&P 500 ETF (SPY)
Enanta Pharmaceuticals Business Overview & Revenue Model
Enanta Pharmaceuticals Earnings Call Summary
Enanta Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.81M | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M |
| Gross Profit | 64.81M | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M |
| EBITDA | -82.41M | -104.51M | -123.48M | -119.22M | -104.25M | -37.99M |
| Net Income | -92.01M | -116.05M | -133.82M | -121.75M | -79.00M | -36.17M |
Balance Sheet | ||||||
| Total Assets | 301.03M | 376.65M | 462.27M | 375.41M | 438.79M | 486.13M |
| Cash, Cash Equivalents and Short-Term Investments | 204.11M | 248.19M | 369.91M | 249.23M | 244.00M | 386.65M |
| Total Debt | 207.10M | 226.06M | 26.51M | 25.26M | 5.33M | 9.58M |
| Total Liabilities | 221.75M | 247.84M | 245.54M | 54.08M | 39.36M | 30.55M |
| Stockholders Equity | 79.28M | 128.81M | 216.74M | 321.33M | 399.43M | 455.58M |
Cash Flow | ||||||
| Free Cash Flow | -43.57M | -96.71M | -112.21M | -86.91M | -70.75M | 5.64M |
| Operating Cash Flow | -23.18M | -78.76M | -103.15M | -84.78M | -70.00M | 7.09M |
| Investing Cash Flow | 57.12M | 58.23M | -53.58M | 54.90M | 36.99M | 19.83M |
| Financing Cash Flow | -25.51M | -27.63M | 198.13M | 20.03M | 3.08M | 8.98M |
Enanta Pharmaceuticals Technical Analysis
Enanta Pharmaceuticals Risk Analysis
Enanta Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $214.86M | 6.66 | 48.34% | ― | ― | ― | |
47 Neutral | $317.09M | ― | -80.64% | ― | -9.94% | 20.81% | |
42 Neutral | $361.60M | -5.02 | -32.21% | ― | ― | 60.40% | |
41 Neutral | $232.98M | ― | -54.43% | ― | -100.00% | 37.10% | |
39 Underperform | $293.64M | -0.30 | -38.06% | 26.12% | ― | 72.33% | |
33 Underperform | $451.83M | -1.78 | -104.35% | ― | ― | 20.71% |
Enanta Pharmaceuticals Corporate Events
On September 30, 2025, Enanta Pharmaceuticals announced a public offering of 6,500,000 shares of its common stock at $10.00 per share, with an option for underwriters to purchase an additional 975,000 shares. The expected net proceeds of approximately $60.6 million will support the company’s operations, with the offering set to close on October 2, 2025, subject to customary conditions.
The most recent analyst rating on (ENTA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
On September 29, 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b study of zelicapavir in high-risk adults for the treatment of respiratory syncytial virus (RSV). The study demonstrated a clinically meaningful reduction in symptom duration, supporting further development towards a Phase 3 trial. This advancement positions Enanta strategically in the RSV treatment market, potentially addressing significant unmet needs for high-risk populations, including older adults and those with chronic heart or lung diseases.
The most recent analyst rating on (ENTA) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
On September 29, 2025, Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults. The study showed that zelicapavir, a novel N-protein inhibitor, significantly improved the time to complete resolution of RSV symptoms and demonstrated a favorable safety profile. The results suggest potential for zelicapavir as a first-in-class RSV treatment, reducing symptom duration and hospitalization rates in high-risk adults.
The most recent analyst rating on (ENTA) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
On August 26, 2025, Enanta Pharmaceuticals appointed Harry R. Trout, III as interim principal financial officer and Kathleen S. Capps as interim principal accounting officer during the medical leave of Paul J. Mellett, the Chief Financial and Administrative Officer. This interim leadership change ensures continuity in the company’s financial operations, with both appointees having extensive experience within the company and the industry.
The most recent analyst rating on (ENTA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
On August 20, 2025, Enanta Pharmaceuticals announced it filed a patent infringement lawsuit against Pfizer Inc. in the Unified Patent Court of the European Union. The suit seeks to determine liability for the use and infringement of Enanta’s European Patent No. EP 4 051 265 in relation to Pfizer’s COVID-19 antiviral, Paxlovid™, across 18 EU countries. This legal action follows the recent grant of the patent by the European Patent Office and parallels ongoing U.S. litigation concerning a related patent. The outcome of this case could significantly impact Enanta’s market position and financial performance, as well as influence its reputation and stock market valuation.
The most recent analyst rating on (ENTA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases, with a robust pipeline targeting respiratory syncytial virus (RSV) and inflammatory diseases.